Update shared on 02 Nov 2025
Fair value Increased 19%Analysts have raised their price target for Xeris Biopharma Holdings from $9.00 to $10.67, citing updated fair value assessments and recalibrated forecasts for the company’s financial outlook.
What's in the News
- Xeris Biopharma Holdings raised its full-year 2025 total revenue guidance to $280 to $290 million, up from the prior range of $260 to $275 million (Key Developments).
Valuation Changes
- Fair Value has increased from $9 to approximately $10.67, reflecting a higher assessment of Xeris Biopharma Holdings' intrinsic worth.
- The Discount Rate remains steady at 6.78 percent, indicating consistent risk assumptions in valuation models.
- The Revenue Growth projection is essentially unchanged at about 21.5 percent, pointing to stable expectations for future sales expansion.
- The Net Profit Margin forecast has decreased modestly from 19.2 percent to 18.3 percent, suggesting slightly lower anticipated profitability.
- The Future P/E ratio has increased from roughly 25.5x to 31.7x, implying that higher valuation multiples are being applied to future earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.